Dr Ian George, Chief Executive Officer
Ian has a background in technology commercialisation and early stage healthcare companies. He co-founded Enigma Diagnostics in 2004 & led the company’s business development activities. Previously he worked as a consultant at The Technology Partnership and prior to that at the Defence Science Technology Laboratory where he was responsible for the formation of several spin-out companies including Enigma Diagnostics and P2i. Ian holds a first class BSc from Cardiff University & completed his PhD at the Roslin Institute, Edinburgh. Ian is a non-executive director of several companies including Discuva, Cambridge Scientific Innovations, Regenerys & Endomagnetics.
Dr Gareth Wakefield, Chief Technical Officer and Co-Founder
Gareth has over 15 years’ experience of commercialising nanotechnology in University of Oxford spin out companies. Following a BSc and PhD in Physics at the University of Bristol and five years post-doctoral research at Oxford, Gareth co-founded Oxonica with Professor Peter Dobson in 1999 commercialising nanoparticles in cosmetics, biotagging and fuel additives. After working with Oxford Advanced Surfaces on display coatings between 2008 and 2013 Gareth co-founded Xerion Healthcare with Dr Townley in 2015.
Dr Helen Townley, Non-executive Director and Co-Founder
Helen is a University Research Lecturer at the University of Oxford where she combines the roles of William Dodd Research Fellow (Nuffield Department of Obstetrics and Gynaecology) and Senior Visiting Research Fellow (Department of Engineering Science). Dr Townley has a BSc and PhD in Biochemistry from the University of Bristol and has been developing Xerion Healthcare’s core technology since 2007.
Dr Carolyn Porter, Non-executive director
Carolyn is Deputy Head of Technology Transfer (Pharma and Biotech) at Oxford University Innovation, a wholly owned subsidiary of the University of Oxford that manages the Universities technology transfer activities. Carolyn has 14 years’ experience of successfully negotiating a range of deal types including University spin-outs and licences, acquisitions, big pharma in/out-licensing, strategic alliances, supply and distribution partnerships. Carolyn acts as non-executive director for a variety of University spin-out companies.